NASDAQ:ARQL - ArQule Stock Price, Forecast & News

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

ArQule, Inc. (NASDAQ:ARQL) issued its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter, compared to analyst estimates of $1.20 million. ArQule had a negative return on equity of 33.10% and a negative net margin of 805.61%. During the same quarter in the previous year, the business posted ($0.05) earnings per share. View ArQule's Earnings History.

ArQule is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for ArQule.

9 equities research analysts have issued twelve-month price targets for ArQule's shares. Their forecasts range from $12.00 to $20.00. On average, they expect ArQule's stock price to reach $17.50 in the next twelve months. This suggests that the stock has a possible downside of 12.5%. View Analyst Price Targets for ArQule.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ArQule.

News coverage about ARQL stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ArQule earned a media sentiment score of -3.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the immediate future. View News Stories for ArQule.

ArQule saw a decrease in short interest during the month of December. As of December 13th, there was short interest totalling 13,850,000 shares, a decrease of 27.4% from the November 28th total of 19,070,000 shares. Based on an average daily trading volume, of 3,990,000 shares, the short-interest ratio is presently 3.5 days. Approximately 12.5% of the company's stock are short sold. View ArQule's Current Options Chain.

Some companies that are related to ArQule include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other ArQule investors own include Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Advanced Micro Devices (AMD), Verastem (VSTM), Novavax (NVAX), Viking Therapeutics (VKTX), Celldex Therapeutics (CLDX), FalconStor Software (FALC), AcelRx Pharmaceuticals (ACRX) and Cronos Group (CRON).

ArQule's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Syquant Capital Sas (0.51%), FNY Investment Advisers LLC (0.38%), Alpine Global Management LLC (0.07%), Calamos Advisors LLC (0.04%), Curbstone Financial Management Corp (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.

ARQL stock was sold by a variety of institutional investors in the last quarter, including Curbstone Financial Management Corp. View Insider Buying and Selling for ArQule.

ARQL stock was purchased by a variety of institutional investors in the last quarter, including Syquant Capital Sas, FNY Investment Advisers LLC, Alpine Global Management LLC, Calamos Advisors LLC, Strs Ohio and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.

Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARQL stock can currently be purchased for approximately $20.00.

ArQule has a market capitalization of $2.42 billion and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.View Additional Information About ArQule.

The official website for ArQule is http://www.arqule.com/.

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]